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Objective—A double-blind, randomized controlled trial showed that low-dose glucocorticoid 
therapy in pediatric ARDS patients is feasible and may improve both ventilation and oxygenation 
indices in these patients. However, the molecular mechanisms underlying potential changes in 
outcomes remain unclear. Based on these clinical findings, this study was designed to examine the 
effects of intravenous methylprednisolone on circulating inflammatory biomarkers in pediatric 
ARDS patients.
Design—Double-blind, placebo-controlled randomized trial with blood collection on study entry 
and day 7.
Setting—Tertiary care children’s hospital.
Patients—Children (0–18 years) with ARDS undergoing mechanical ventilation.
Interventions—35 children were randomized within 72 hours of mechanical ventilation. The 
glucocorticoid group received methylprednisolone 2 mg/kg loading dose followed by 1 mg/kg/day 
continuous infusion from days 1–7. Both groups were ventilated following the ARDSnet 
recommendations. WBC and differential cell counts, plasma cytokines and CRP levels, and 
coagulation parameters were analyzed on days 0 and 7.
Results—At study entry, the placebo group had higher IL-15 and basophil levels. On day 7, in 
comparison to study entry, the placebo group had lower IL-1α, IFN-γ and IL-10 levels. The 
glucocorticoid group had lower INF-α, IL-6, IL-10, MCP-1, G-CSF and GM-CSF levels, and 
higher IL-17α levels on day 7 in comparison to study entry. Total and differential cell counts 
remained unchanged within the placebo group between days 0 and 7, whereas in the 
glucocorticoid group total WBC and platelets counts were increased on day 7. Pearson’s 
correlation studies within the placebo and glucocorticoid groups revealed positive and negative 
correlations between cytokine levels, cell counts, coagulation parameters and relevant clinical 
parameters of disease severity identified in our previous study. Multiple regression models 
identified several cytokines as predictors for alterations in clinical parameters of disease severity.
Conclusion—This pilot study shows the feasibility of simultaneously measuring multiple 
inflammatory cytokines, cell counts and coagulation parameters in pediatric ARDS patients. We 
report statistical models that may be useful for future, larger trials to predict ARDS severity and 
outcomes.
Keywords
ARDS; lung injury; cytokines; chemokines; mediators; pediatrics; steroids; glucocorticoids; 
inflammation
INTRODUCTION
The clinical constellation of acute hypoxia and bilateral chest X-ray infiltrates was first 
described by Ashbaugh in 1967[1] and was later defined as “Acute Respiratory Distress 
Syndrome” (ARDS) by the American-European Consensus Conference (AECC) in 1994[2]. 
Although mortality rates in both the adult[3] and pediatric populations[4] are declining, 
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substantial morbidity persists[5], resulting in a steadily increasing burden on our health care 
budget.
Despite the clinical consequences and health care costs associated with ARDS, the 
development of new therapeutic strategies has faced multiple challenges over the years. 
Currently, oxygen supplementation and lung-protective ventilation strategies remain the 
cornerstones of ARDS treatment, although ultimately both therapies can exacerbate pre-
existing lung damage and promote pro-inflammatory cytokine release[6]. Multiple other 
therapies including nitric oxide[7], surfactant[8], prostaglandins[9], fluid balance[10] and 
high frequency ventilation[11] have failed to improve survival rates. To ameliorate the 
exaggerated pulmonary and systemic proinflammatory response occurring in ARDS 
patients, intravenous glucocorticoid therapy has been studied in the adult population[12]. 
Early initiation of low-dose glucocorticoid therapy appears to provide particular therapeutic 
benefits in adults by reducing lung injury scores, ventilator days and mortality rates[13].
The scarcity of new therapeutic approaches for ARDS is partly related to our lack of 
understanding the underlying molecular mechanisms promoting this disease. Dysregulation 
of inflammatory mediator secretion both locally and systemically contributes to the 
development of ARDS. Plasma IL-1β, IL-6, IL-8, and IL-10 levels are elevated in adult 
ARDS patients[14], while TNF-α and IL-6 levels are increased in the BAL fluid[15]. 
Importantly, both serum and BAL cytokine levels correlate with increased mortality 
rates[15]. The large majority of these findings were obtained in adult studies and our 
knowledge about changes in inflammatory markers in pediatric ARDS patients is very 
limited[16]. As the pulmonary and immune systems of children are still in development, 
differences in their immune and inflammatory responses compared to adults are to be 
expected.
Not only are inflammatory mediator signaling networks incredibly complex but we also lack 
a clear understanding of their cellular sources. While macrophages, neutrophils and 
lymphocytes are known to produce a variety of pro- and anti-inflammatory mediators in the 
lung[17, 18], we have recently confirmed that alveolar epithelial cells also secrete 
substantial amounts of inflammatory cytokines[19–21]. Due to the complexity of cytokine 
signaling and cellular interactions, which ultimately determine the inflammatory 
microenvironment in the lungs of ARDS patients, employing a broad-spectrum anti-
inflammatory approach by using intravenous glucocorticoids constitutes a reasonable 
clinical approach while we continue our search for more specific molecular targets.
The effects of intravenous glucocorticoid therapy in the pediatric population, including 
potentially adverse consequences for the developing child, are poorly defined. We recently 
reported the first randomized controlled pilot trial showing the feasibility of 
methylprednisolone therapy in children with ARDS and potential improvements in their 
oxygenation, ventilation and plateau pressures[22]. However, the molecular mechanisms 
underlying these clinical changes remained unknown. This study builds on the changes in 5 
clinical parameters identified in our previous publication[22]. These included (1) P/F ratio 
on day 8, (2) plateau pressures (PP) on day 2, (3) pCO2 levels on day 2, (4) racemic 
epinephrine requirement following extubation, and (5) O2 requirement at PICU discharge. 
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This is the first attempt to dissect the molecular mechanisms responsible for the observed 
alterations in these 5 clinical parameters by determining alterations in pro- and anti-
inflammatory mediator concentrations in response to early, low-dose intravenous 
glucocorticoid therapy. In this follow-up study our main goal consisted in identifying 
potential ARDS biomarkers such as cytokines, cell counts, CRP levels and coagulation 




A total of 35 children (0–18 years) diagnosed with ARDS as defined by the Berlin 
definition[23] were initially randomized to placebo or glucocorticoid groups within 72 hours 
of mechanical ventilation as described in our previous study[22] (ClinicalTrials.gov number: 
NCT01274260). Briefly, exclusion criteria for study enrollment were exposure to 
glucocorticoids at the time of screening, terminal illness, hospice care, immunosuppressed 
status, extensive burns, adrenal insufficiency, vasculitis, diffuse alveolar hemorrhage, 
invasive fungal infection, chronic liver disease, gastrointestinal bleed within the past 1 
month, or conditions with an estimated 6-month mortality of >50%. The steroid and placebo 
groups were similarly matched (p>0.05) in regards to the following patient characteristics: 
sex, race, PRISM III score, PIM-2 score, P/F ratio, PEEP, tidal volume, mean airway 
pressure, blood gas pH. PaCO2, and number of lobes affected on chest X ray. Furthermore, 
ARDS etiologies were similar between the two groups with pneumonia being the most 
common cause, followed in order of frequency by bronchiolitis, aspiration, trauma, TRALI, 
near drowning, hydrocarbon ingestion, preterm birth, and asthma. The duration of 
mechanical ventilation was 9.74±6.62 vs 9.59±5.21 days in the glucocorticoid and the 
placebo group (p=0.94), respectively. Two patients died in the placebo group, whereas all 
survived in the glucocorticoid group (p=0.15). No patients abandoned the study. 
Importantly, although we enrolled a total of 35 patients into our study, the number of 
patients across all study days was not a constant for either group since the numbers of 
patients in both groups decreased with increasing number of days. Not all cytokines were 
present in all subjects and by day 7 some patients from each study group had improved and 
were no longer on a ventilator. Therefore, each table contains the number of patients in 
which a certain cytokine or inflammatory parameter was detected or studied.
Pediatric ARDS was defined as (1) acute onset of disease (within 7 days) that could not be 
explained by acute left heart failure, (2) new, bilateral infiltrates on chest X ray consistent 
with parenchymal pulmonary disease, and (3) P/F ratio <300[23]. Both study groups were 
mechanically ventilated on the Servo i ventilators (Maquet, Inc.) in a patient-regulated 
volume control (PRVC) mode, with or without synchronized intermittent mandatory 
ventilation (SIMV), and with tidal volumes of 6–8 ml/kg (based on ideal body weight in 
obese children and actual body weight in non-obese children), as suggested by the ARDSnet 
recommendations modified for children[24].
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Glucocorticoid group patients received methylprednisolone 2 mg/kg loading dose followed 
by 1 mg/kg/day continuous infusions from day 1 to day 7. The placebo group received 
equivalent saline infusions.
Blood sample collection
On days 0 and 7 of the study, we collected 1 ml of whole blood in a lavender-top, K2EDTA-
containing tube. The samples were manually transferred on ice within 30 min from the blood 
draw to the hospital laboratory and centrifuged for 10 min at 1000 × g at 4°C. Plasma 
samples were stored at −80°C. Clinically required WBC and differential cell counts, C-
reactive protein (CRP) levels and coagulation parameters (PT, PTT, fibrinogen) from days 0 
and 7 were retrospectively analyzed when available.
Luminex assay
Plasma mediator concentrations were determined using the Millipore Human Cytokine panel 
(Millipore, Billerica, MA) following the manufacturer’s instructions. All samples were run 
in duplicates (or triplicates if plasma was available); 38 mediators were assayed and 
concentrations were expressed in [pg/mL]: EGF, eotaxin, FGF-2, Flt3L, fractalkine, G-CSF, 
GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17α, IP-10, MCP-1, MCP-3, 
MDC, MIP-1α, MIP-1β, sCD40L, TGF-α, TNF-α, TNF-β and VEGF.
Statistical analyses
Univariate (descriptive statistics, frequency distributions), bivariate (Fisher’s test for 
variability, t-tests, Pearson’s correlations) and multivariate analyses (linear regressions using 
the least squares method) were used to evaluate the effects of glucocorticoids in pediatric 
ARDS. StatPlus (AnalystSoft, Inc.) was used for generating descriptive statistics and 
frequency distributions for all variables (cytokines, chemokines, and growth factors) at days 
0 and 7 for the placebo and glucocorticoid groups. Prism 6 (GraphPad Software, Inc.) was 
used for bivariate analyses comparing within and between the glucocorticoid vs. placebo 
groups at days 0 and 7. Depending on the data distribution, we used either the unpaired t-test 
(parametric) or the Mann-Whitney U test (nonparametric) for group comparisons. We also 
generated a correlation matrix for pairwise associations of Pearson correlation coefficients 
with simultaneously run t-tests. These results were used for pathway analysis of the 
measured mediators.
Pairs of variables demonstrating strong correlation coefficients (R ≥0.7, p ≤0.01) were used 
for building multivariate regression models to predict the 5 relevant clinical outcomes 
reported in our previous study[22], which included PaO2/FiO2 (P/F) ratio on day 8, plateau 
pressure and PaCO2 on day 2, racemic epinephrine following extubation, and supplemental 
oxygen at PICU discharge.
Bivariate correlation matrices and bar graphs were prepared using only raw data without 
adjustment or imputation of missing data points. Rarely, imputation of missing values for 
immune mediators was necessary to build the multivariate regression models explaining or 
contributing to glucocorticoid treatment-associated clinical outcomes. Immune mediator 
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values falling at or below the standard curve were assigned the lowest value on the 
generated standard curve. Immune factors falling at or above the standard curve were 
assigned the highest value on the generated standard curve. Since these were exploratory 
hypothesis-generating analyses we did not make corrections for multiple comparisons 
between groups.
The number of subjects (n) per group is listed in each table legend. We selected a 95% 
confidence interval.
RESULTS
1. Plasma cytokine levels, WBC counts, CRP levels, and coagulation tests
a. Between-group differences—No baseline differences in any of the 38 cytokines 
occurred on day 0 between the placebo and GC groups, except for higher IL-15 levels in the 
placebo group (Table 1A and Figure 1A). We found no differences in total WBC counts 
(including neutrophils, monocytes, lymphocytes, eosinophils and basophils), platelet counts, 
CRP levels and coagulation parameters (including PT, PTT and fibrinogen levels) between 
the placebo and GC groups on day 0.
On day 7, the difference in IL-15 levels between the placebo and the GC groups was no 
longer present. Although total WBC and platelet counts remained unchanged between the 
two groups, basophil percentages were elevated on day 7 in the placebo group (Table 1B 
and Figure 1A). We had insufficient data points for statistical analysis of CRP levels, PT, 
PTT, and fibrinogen levels on day 7.
b. Within-group (time-dependent) changes—By day 7, compared to study entry, the 
placebo group (Table 2 and Figure 1B) had lower IL-1α, IFN-γ, and IL-10 levels but no 
changes occurred in total and differential WBC (neutrophils, monocytes, lymphocytes, 
eosinophils and basophils) counts, platelet counts, PT, PTT, fibrinogen or CRP levels.
By day 7, compared to study entry, the GC group (Table 3, Figures 1B and 1C) had 
increased IL-17α levels but lower IFN-α, IL-6, IL-10, MCP-1, G-CSF and GM-CSF levels. 
The GC group also showed increased platelet and total WBC counts, without any changes in 
differential WBC counts.
2. Pairwise correlations of serum cytokines and other parameters
Candidate biomarkers demonstrating differences between the placebo and GC groups, or 
between days 0 and 7 within these groups, were analyzed as Pearson correlations. Tables 4 
and 5 depict positive and negative relationships between cytokines, cell counts, non-cellular 
inflammatory markers (PT, PTT, fibrinogen, CRP), and the 5 relevant clinical outcomes 
identified in our previous study[22], specifically: (1) P/F ratio on day 8, (2) plateau 
pressures (PP) on day 2, (3) PCO2 levels on day 2, (4) racemic epinephrine requirement 
following extubation, and (5) O2 requirement at PICU discharge.
a. In the Placebo Group—Although only IL-15 levels were increased on day 0 in the 
placebo group compared to the GC group, IL-15 positively correlated with MIP-1β levels on 
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day 7 and negatively with monocyte counts on day 0 (Table 4). O2 requirement at ICU 
discharge and racemic epinephrine after extubation were also positively correlated with 
IL-15 levels on day 7.
Other cytokines of particular interest were IL-1α, IFN-γ and IL-10 since they were 
decreased on day 7 (Table 2). IL-1α levels in the placebo group on day 0 positively 
correlated with eotaxin, GM-CSF, IL-10, IL-7, MIP-1α, MIP-1β and TNF-α levels. 
Interestingly, IL-1α levels positively correlated with the anti-inflammatory cytokine IL-10 
but not with the WBC counts, CRP levels or coagulation parameters (PT, PTT, fibrinogen). 
O2 requirement at ICU discharge also positively correlated with IL-1 α levels on day 0.
IFN-γ levels on day 0 positively correlated with Flt-3L, fractalkine, IL-17α, IL-1RA and 
IP-10 levels. On day 7, IFN-γ levels positively correlated with racemic epinephrine 
requirement after extubation.
IL-10 levels on day 0 positively correlated with eotaxin, Flt-3L, GM-CSF, IL-1RA, IL-1α, 
IL-6, IL-7, IP-10, MCP-1, MIP-1β and TNF-α levels, as well as with PT and PTT levels. On 
day 7, IL-10 levels in the placebo group positively correlated with Flt-3L, IL-6, IL-8, 
MCP-1 and MIP-1α levels. Interestingly, IL-10 levels on both days 0 and 7 positively 
correlated with O2 requirement at ICU discharge in the placebo group.
b. In the GC Group—Cytokines of particular interest were IL-17α, IFN-α, IL-10, IL-6, 
MCP-1, G-CSF and GM-CSF since their levels were altered on day 7 compared to day 0 
(Table 3).
IL-17α positively correlated with IL-2 levels on day 0 (Table 5), but not with any other 
cytokines, cell counts, CRP levels, coagulation parameters, or clinical outcomes.
On day 0, IFN-α levels positively correlated with IL-1RA, IL-7, IL-8, MCP-1 levels and 
monocyte counts (Table 5). This positive correlation between IFN-α levels and monocyte 
counts persisted on day 7.
IL-10 levels positively correlated on day 0 with EGF, fractalkine, IFN-α, GRO, IL1RA, 
IL-8, MCP-1, and MIP-1α, whereas on day 7, IL-10 levels positively correlated with IL-15 
levels (Table 5). Interestingly, IL-10 levels on day 7 positively correlated with PPs on day 2.
IL-6 levels positively correlated with EGF, IL-8 and monocyte counts on day 0 (Table 5), 
but not with any clinical outcomes on days 0 or 7.
MCP-1 levels positively correlated on day 0 with EGF, FGF-2, eotaxin, GM-CSF, 
fractalkine, IFN-α, GRO, IL-10, IL-1RA, IL-8, MIP-1α, MIP-1β and basophil levels (Table 
5). On day 7, the positive correlation between MCP-1 and EGF, FGF-2 and IL-8 persisted 
but MCP-1 also positively correlated with TGF-α and VEGF levels. MCP-1 levels on day 7 
also correlated with PTT levels on day 0.
On day 7, we found a negative correlation between G-CSF levels and neutrophil counts but 
a positive correlation between G-CSF levels and eosinophil counts (Table 5).
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GM-CSF levels positively correlated on day 0 with several chemokines (eotaxin, GRO, 
IL-8, MCP-1), cytokines (IFN-α, IL-1RA and IL-10) and growth factors (EGF, FGF-2) in 
the GC group (Table 5). Similar to G-CSF, on day 7 GM-SCF levels inversely correlated 
with neutrophil counts but positively correlated with eosinophil counts. None of the clinical 
parameters of interest correlated with GM-CSF levels on days 0 or 7.
3. Cytokines, cell counts, CRP levels and coagulation parameters as predictors for clinical 
outcomes
Based on the alterations in 5 clinical outcomes identified in our previous study[22], (P/F 
ratio on day 8, plateau pressures (PP) on day 2, PCO2 levels on day 2, racemic epinephrine 
requirement following extubation, and O2 requirement at PICU discharge), we set these 
clinical outcomes as dependent variables and used pairwise correlations from Tables 4 and 5 
as predictors for these outcomes (Tables 6A–C).
In the placebo group, FGF levels on day 0 were negative predictors whereas IL-7 levels 
were positive predictors for improved P/F ratios on day 8 (Table 6A). In the GC group, 
WBC and neutrophil counts on day 0 positively predicted improved P/F ratios on day 8, 
whereas fractalkine levels and lymphocyte counts on day 7 were negative predictors.
No variables from day 0 were predictive of plateau pressures in either the placebo or the GC 
group (Table 6A). On day 7, IL-10 levels and lymphocyte counts were positive predictors 
for plateau pressures in the placebo group, whereas IL-12(p70) levels were a negative 
predictor.
Neither cytokines, nor cell counts, coagulation parameters, nor CRP levels were predictive 
of PaCO2 levels on day 2 in the placebo or GC group (Table 6A).
In the placebo group, MCP-1 levels on day 0 and IFN-γ levels on day 7 were positive 
predictors for racemic epinephrine requirement as were lymphocyte counts on both days 0 
and 7 (Table 6B).
In the placebo group, several cytokines (IL-10, IL-1RA, IL-6, MCP-1, MIP-1β) and 
lymphocyte counts from day 0 were positive predictors for supplemental O2 requirement at 
ICU discharge, whereas Flt-3L and IL-17α levels were negative predictors (Table 6B). On 
day 7, eotaxin, Flt-3L and IL-15 levels were positive predictors of O2 requirement at ICU 
discharge, whereas IL-10 levels were a negative predictor. In the GC group, no variables 
were predictive of O2 requirement at ICU discharge on day 0, but PTT levels were a 
negative predictor on day 7.
Table 6C demonstrates the r, adjusted r2 and p-ANOVA values for the described alterations 
in clinical parameters and the different groups and study days.
DISCUSSION
Based on our recent pilot trial describing the effects of low-dose glucocorticoid (GC) 
therapy in early pediatric ARDS[22], we identified 5 clinical parameters of interest, namely 
P/F ratio on day 8, plateau pressures (PP) on day 2, PCO2 levels on day 2, racemic 
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epinephrine requirement following extubation, and O2 requirement at PICU discharge. We 
now designed this study to analyze inflammatory mediators, WBC and differential cell 
counts, CRP levels and coagulation factors between placebo- and GC-treated children on 
study days 0 and 7, and to determine if these parameters could explain the alterations in 5 
clinical outcomes reported in our previous study[22]. Despite following all patients for up to 
28 days, the number of samples collected past day 7 was too small for statistical analysis. 
However, since in adults with ARDS the benefits of GC treatment occurred as far out as 32 
days[25], future trials should determine the progression or resolution of inflammatory 
processes past the first week of treatment.
The pathophysiology of ARDS is not limited to the lung but is associated with a systemic 
inflammatory response that provides a rationale for systemic GC therapy[26]. Interestingly, 
non-resolving ARDS has been linked to GC resistance[27], while prolonged low-dose GC 
therapy downregulated systemic inflammation[26]. Of note, all our measurements were 
performed in plasma and not BAL samples, since BAL is not routinely performed in 
pediatric ARDS patients and often has no diagnostic or therapeutic value. In addition, due to 
the heterogeneous pattern of lung disease in ARDS, the technical difficulty of performing 
BAL in small children and the high dilution factor of BAL fluid in a small pediatric lung, 
this procedure is not standard practice in acutely ill children with ARDS.
The only baseline difference in cytokine levels between the two groups was a higher IL-15 
level in the placebo group (Table 1A and Figure 1A). IL-15 orchestrates T-cell responses 
during viral infections[28] and promotes T cell differentiation[29]. Interestingly, in our 
previous study[22], pneumonia and bronchiolitis were the two most common etiologies for 
ARDS in both study groups. Although IL-15 establishes homeostasis of NK and CD8+ T 
cells, emerging literature also links IL-15 to anti-viral T-cell responses in acute infections. In 
fact, IL-15 KO mice showed lower mortality following influenza infection despite no 
changes in viral loads[30] and the combination of IL-15 with hydrocortisone was a 
particularly powerful activator of NK cells[31]. In our study, lymphocyte counts were 
similar at baseline and at day 7, whereas total WBC and platelet counts were elevated on day 
7 in the GC group (Table 3 and Figure 1C). Systemic GC treatment may plausibly cause 
increased bone marrow release of WBCs, decreased vascular emargination and decreased 
lung infiltration[32]. To evaluate this hypothesis, plasma, interstitial and BAL cell counts 
would need to be collected simultaneously, which may be very challenging in small 
children. Of note, in adults, methylprednisolone reduced BAL neutrophilia and albumin 
levels[33]. Our Pearson’s correlations revealed an inverse relationship between IL-15 and 
monocytes on day 0, whereas IL-15 positively correlated with MIP-1β on day 7 (Table 4).
Furthermore, IL-15 levels positively correlated with racemic epinephrine use after 
extubation and supplemental O2 at ICU discharge (Table 4), two parameters of interest 
identified in our previous study[22]. It is possible that although total lymphocyte counts 
were unchanged, more lymphocytes were activated by the elevated IL-15 levels in the 
placebo group, resulting in increased O2 and racemic epinephrine requirements. This 
hypothesis may be supported by the fact that IL-1α and IFN-γ, other T-cell cytokines, also 
showed a positive correlation with O2 at ICU discharge and racemic epinephrine 
requirements in the placebo group (Table 4). The multiple regression model (Tables 6A–C) 
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revealed that in the placebo group on day 7, IL-15 levels positively correlated with O2 
requirement at ICU discharge, but not with other clinical parameters of disease severity.
The increased IL-17α levels in the GC group on day 7 also merit further discussion (Table 3 
and Figure 1C). IL-17α is closely linked to IL-22 as both cytokines coordinate aspects of 
innate lung immunity[34]. A major source for these cytokines during acute infections are γδ-
T cells and NK cells, whereas CD4+ T helper (Th17) cells contribute more to vaccine-
induced immunity[34]. With the discovery of Th17 cells, a role for IL-17α in ARDS was 
proposed[35]. In the lung epithelium, the primary target for IL-17α, this cytokine stimulates 
the production of antimicrobial proteins, neutrophil chemoattractants and macrophage 
differentiation, ultimately promoting pulmonary fibrosis[36].
Some investigators found that early activation of the IL-1β/IL-17α axis resulted in a 
proinflammatory effect and increased pulmonary fibrosis [37], whereas others showed that a 
lack of γδT cell-derived IL-17α actually increased lung fibrosis[38]. In a rodent sepsis 
model, IL-17α neutralization improved survival by decreasing neutrophil infiltration, IL-6 
and TNF-α levels[36]. Therefore, with our current knowledge a final pro- or anti-
inflammatory role cannot yet be assigned to IL-17α and the timing of IL-17α peaks may 
determine its function in a particular environment. Interestingly, IL-15, the only cytokine 
difference between the study groups, can decrease IL-17α levels and IL-17α-mediated lung 
injury[39].
In a rodent model of LPS-induced ARDS, methylprednisolone reduced IL-17α levels and 
ameliorated lung injury[40]. Although IL-17α was unchanged between the study groups, its 
levels were increased in the GC group on day 7 (Table 3 and Figure 1C). We speculate that 
an increase in IL-17α in the GC group could be related to the clinical improvements 
reported in our previous study[22]. Interestingly, total WBC but not WBC differential 
counts were elevated on day 7 in the GC group (Table 3 and Figure 1C). It is conceivable 
that the increased IL-17α levels were caused by increased activation of lymphocytes without 
changes in differential lymphocyte counts. Although we attempted to rescue lymphocytes 
from frozen buffy coat samples to study the Th17 population, we were unable to obtain 
adequate cell numbers. However, fresh lymphocytes for Th17 subtyping should be collected 
in future studies.
We also found a positive correlation of IL-17α with IL-2 levels in the GC group on day 0 
(Table 5). IL-2, another T-cell cytokine, regulates T-cell proliferation, including Tregs, 
which in turn regulate Th17 cells[41]. In our multiple regression model (Table 6), IL-17α 
was a positive predictor for an increased O2 requirement at ICU discharge in the placebo 
group, potentially indicating a proinflammatory role for IL-17α.
The alterations in IL-10 levels also appeared intriguing. IL-10 is generally considered an 
anti-inflammatory cytokine and its role in ARDS is well recognized. We found no 
differences in IL-10 levels between the study groups despite some improvements in clinical 
disease parameters (P/F ratio, PPs, racemic epinephrine requirement, O2 requirement at ICU 
discharge) as shown in our previous study[22]. Nevertheless, we found a decrease in IL-10 
levels within both groups on day 7 (Tables 2 and 3, Fig 1B), potentially coupled with a 
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simultaneous downregulation of several proinflammatory cytokines, such as IL-1α and IFN-
γ in the placebo group, and IL-6 and neutrophil chemoattractants (MCP-1, G-CSF and GM-
CSF) in the GC group. Despite lower neutrophil chemoattractant levels in the GC group, 
differential neutrophil counts were unchanged on day 7. Elevated total WBC and platelet 
counts may again be more related to a GC-induced release of hematopoietic cells and 
decreased tissue emargination than chemotaxis. Nevertheless, a potential relationship 
between neutrophils and IL-10 is possible, since in the placebo group several 
chemoattractants, including eotaxin, GM-CSF and MCP-1 on day 0, and IL-8 and MCP-1 on 
day 7 positively correlated with IL-10 levels (Table 4). In the GC group, IL-10 levels 
positively correlated with neutrophil chemoattractants (GM-CSF, GRO, IL-8 and MCP-1) 
before (day 0) but not after GC therapy (day 7).
Interestingly, a positive correlation between IL-10 levels and O2 requirement at ICU 
discharge, one of the clinical parameters of interest identified in our previous study[22], 
occurred in the placebo group on both days 0 and 7 (Table 4) and our multiple regression 
model identified IL-10 as a positive predictor for O2 requirement at ICU discharge on both 
days 0 and 7 (Table 6), supporting a beneficial role of IL-10 in the resolution of ARDS.
While IL-10 levels positively correlated with plateau pressures in the GC group on day 7 
(Table 5), in our multiple regression model (Table 6), IL-10 levels on day 7 predicted 
improved plateau pressures in the placebo but not the GC group. Thus, it remains unclear 
how IL-10 relates to the GC-mediated improvement in plateau pressures observed in our 
previous study[22].
Clear limitations of this pilot study consist in its small sample size and the lack of functional 
assays uncovering the mechanistic and functional consequences of the mediators measured. 
While our original study[22] was designed to show feasibility of patient recruitment, 
randomization and sample collection, in this follow-up study our main goal consisted in 
identifying potential ARDS biomarkers such as cytokines, cell counts, CRP levels and 
coagulation parameters. Due to these limitations, we caution the reader to not draw any 
major conclusions on the effects of GC therapy on clinical outcomes in pediatric ARDS 
patients while the specific molecular mechanisms underlying potential GC effects in 
pediatric ARDS remain to be unraveled. Nevertheless, this study unveiled that inflammatory 
mediators can be successfully measured in pediatric patients with commercially available 
techniques. Our correlation and regression models can aid future studies to focus on a more 
concise number of molecular targets and encourage the critical mind to speculate on new 
potential targets for ARDS therapies.
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EGF epidermal growth factor
FGF-2 fibroblast growth factor-2
Flt3L fms-like tyrosine kinase 3 ligand
G-CSF granulocyte-colony stimulating factor
GM-CSF granulocyte monocyte-colony stimulating factor





















MCP-1 monocyte chemotactic protein-1
MCP-3 monocyte chemotactic protein-3
MDC macrophage-derived chemokine
MIP-1α macrophage inhibitory protein-1α
MIP-1β macrophage inhibitory protein-1β
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sCD40L soluble CD40 ligand
TGF-α transforming growth factor-α
TNF-α tumor necrosis factor-α
TNF-β tumor necrosis factor-β
VEGF vascular endothelial growth factor
WBC white blood cells
PT prothrombin time
PTT partial thromboplastin time
CRP C-reactive protein
ICU intensive care unit
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1. A recent RCT in pediatric ARDS patients showed that low-dose glucocorticoid 
therapy in pediatric ARDS patients is feasible and may improve both ventilation 
and oxygenation indices.
2. The molecular mechanisms underlying potential changes in these outcomes 
remained unclear.
3. This study was designed to examine the effects of intravenous 
methylprednisolone on circulating inflammatory biomarkers in pediatric ARDS 
patients.
4. We show the feasibility of simultaneously measuring multiple inflammatory 
cytokines, cell counts and coagulation parameters in pediatric ARDS patients.
5. We report statistical models that may be useful for future, larger trials to predict 
ARDS severity and outcomes.
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Figure 1. Comparisons of inflammatory meditators
Figure 1A shows comparisons of cytokine levels and cell counts between the placebo and 
the glucocorticoid (GC) groups on days 0 and 7. Using an unpaired 2-tailed t-test with a p-
value of <0.05 as our level of significance (*), the only alteration in cytokine levels was an 
elevated IL-15 concentration [pg/mL] in the placebo group on day 0 and a higher basophil 
count in the placebo group on day 7; (mean±SEM).
Figure 1B shows decreased IL-1α, IFN-γ and IL-10 levels in the placebo group on day 7 
(D7), and decreased IL-10 levels in the GC group on day 7. Cytokine concentrations are 
depicted in pg/mL (mean±SEM). A p-value of <0.05 was considered significant (#).
Figure 1C shows elevated IL-17α levels and decreased IFN-α, IL-6, MCP-1, G-CSF and 
GM-CSF levels on day 7 (D7) in the glucocorticoid (GC) group. Cytokine concentrations 
are depicted in pg/mL (mean±SEM). IL-17α levels were analyzed using an unpaired t-test 
(indicated by ^). The rest of the cytokine levels were analyzed using a 2-tailed Mann-
Whitney test based on a Fisher test and data are depicted as median±SE. A p-value of <0.05 
was considered significant (#).
Schwingshackl et al. Page 17

























Schwingshackl et al. Page 18
Table 1
Comparison of cytokine levels and cell counts between placebo and the glucocorticoid 
(GC) groups on days 0 and 7
Table 1A shows an increased IL-15 concentration on day 0 and Table 1B an increased basophil count on day 7 
















basophils ↑ - 0.008
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Table 2
Comparison of cytokine levels within the placebo group between days 0 (D0) and 7 (D7): ↓ arrows indicate a 
decrease in cytokine levels. (*) indicate data analyzed using an unpaired 2-tailed t-test, whereas IL-10 levels 
were analyzed using a 2-tailed Mann-Whitney test based on a Fisher test. A p-value of <0.05 was considered 
significant (#). n=number of subjects.
Placebo Days 0 vs 7
Cytokines: p n: day 0, day 7
IL–1a* ↓ 0.036 6,6
INF–y*↓ 0.037 6,6
IL–10 ↓ 0.002 7,6
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Table 3
Comparison of cytokine levels within the glucocorticoid (GC) group between days 0 (D0) and 7 (D7): ↑ and ↓ 
arrows indicate an increase or decrease in cytokine levels, respectively. IL-17α levels were analyzed using an 
unpaired t-test (indicated by ^) and are depicted as mean±SEM. The rest of the cytokine levels were analyzed 
using a 2-tailed Mann-Whitney test based on a Fisher test. A p-value of <0.05 was considered significant (#). 
n=number of subjects.
GC Days 0 vs 7
Cytokines: p n: day 0, day 7
IL-17a^ ↑ 0.045 5,2
INF-α ↓ 0.026 6,6
IL-6 ↓ 0.003 7,6
IL-10 ↓ 0.035 7,6
MCP-1 ↓ 0.004 7,8
G-CSF ↓ 0.004 4,8
GM-CSF ↓ 0.026 7,7
WBCs ↑ 0.041 8,7
platelets ↑ 0.034 8,7
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Table 4
Placebo group Pearson’s correlation table showing pairwise comparisons of cytokine levels, cell counts and 
clinical parameters of disease severity: r is the Pearson’s correlation coefficient. A p-value of <0.01 was 
considered significant and was derived from a paired, 2-tailed t-test. n=number of subjects (Day 0: cytokines 
n=8–18, cell counts n=18, clinical parameters of disease severity n=17. Day 7: cytokines n=3–7, cell counts 
n=7, clinical parameters of disease severity n=7).
IL-15
Placebo Day 0 r p
monocytes −1.0 0.001
Placebo Day 7 r p
MIP-1β 1.0 0.007
O2 at discharge 1.0 0.001
Racemic epi 1.0 0.001
IL-1α









O2 at discharge 0.8 0.008
IFN-y






Placebo Day 7 r p
racemic epi 0.9 0.006
IL-10
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IL-10











O2 at transfer 0.8 ≤0.000






O2 at discharge 1.0 ≤0.000
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Table 5
Glucocorticoid (GC) group Pearson’s correlation table showing pairwise comparisons of cytokine levels, cell 
counts and clinical parameters of disease severity: r is the Pearson’s correlation coefficient. A p-value of <0.01 
was considered significant and was derived from a paired, 2-tailed t-test. n=number of subjects (Day 0: 
cytokines n=8–16, cell counts n=16, clinical parameters of disease severity n=16. Day 7: cytokines n=6–8, cell 
counts n=8, clinical parameters of disease severity n=8).
IL-17α
GC Day 0 r p
IL-2 1.0 0.008
IFN-α






GC Day 7 r p
monocytes 0.9 0.008
IL-10









GC Day 7 r p
IL-15 1.0 0.009
PP Day 2 0.9 0.004
MCP-1
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MCP-1















PTT-Day 0 0.9 0.005
G-CSF


















GC Day 0 r p
EGF 0.9 0.002
IL-8 0.8 0.002
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IL-6
GC Day 0 r p
monocytes 0.7 0.004
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Table 6
Tables 6A and B. Multiple regression models based on clinical parameters of disease severity identified in our 
previous study[22] using the least squared method.
Table 6C reports the Pearson’s r, adjusted r2 and p-ANOVA values for the data in Tables 6A and B.
Tables 6A
P/F ratio day 8
vs placebo D0, n=7 Coefficients SE p
Intercept 227 14.7 ≤0.000
FGF-2 −2.480 0.266 0.001
IL-7 11.4 1.910 0.004
vs placebo D7, n=5 Coefficients SE P
none
vs GC, n=9 Coefficients SE p
Intercept 119.044 41.933 0.025
WBC 5.386 5.956 0.396
Neutrophils 1.855 1.283 0.192
vs GC D7, n=7 Coefficients SE p
Intercept 456.169 23.987 ≤0.000
fractalkine −1.256 0.360 0.025
lymphocytes −2.419 0.646 0.020
PP day 2
vs placebo D0, n=18 Coefficients SE P
none
vs placebo D7, n=17 Coefficients SE P
Intercept 7.743 0.497 0.001
IL-10 0.115 0.006 ≤0.000
IL-12P70 −0.005 0.001 0.002
lymphocytes 0.071 0.004 ≤0.000
vs GC D0, n=15 Coefficients SE p
none
vs GC D7, n=8 Coefficients SE p
none
PaCO2 day 2
vs placebo D0, n=18 Coefficients SE P
none
vs placebo D7, n=17 Coefficients SE P
none
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vs GC D0, n=15 Coefficients SE P
none




vs placebo D0, n=17 Coefficients SE P
Intercept 0.755 0.216 0.004
MCP-1 ≤0.000 ≤0.000 0.016
lymphocytes 0.015 0.005 0.012
vs placebo D7, n=7 Coefficients SE P
Intercept 0.175 0.154 0.318
IFN-y 0.083 0.021 0.017
lymphocytes 0.017 0.006 0.039
vs GC D0, n=16 Coefficients SE p
none
vs GC D7, n=8 Coefficients SE p
none
O2 at discharge
vs placebo D0, n=17 Coefficients SE P
Intercept 2.017 0.008 ≤0.000
Flt-3L −0.002 ≤0.000 0.001
IL-10 ≤0.000 ≤0.000 0.001
IL-1RA ≤0.000 ≤0.000 ≤0.000
IL-6 ≤0.000 ≤0.000 0.004
MCP-1 ≤0.000 ≤0.000 0.013
MIP-1β 0.001 ≤0.000 ≤0.000
lymphocytes ≤0.000 ≤0.000 0.007
vs placebo D7, n=7 Coefficients SE P
Intercept 1.933 0.004 ≤0.000
eotaxin ≤0.000 ≤0.000 0.010
Fit-3L ≤0.000 ≤0.000 0.003
IL-10 −0.002 ≤0.000 0.008
IL-15 0.027 0.001 0.001
vs GC D0, n=16 Coefficients SE P
none
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vs GC D7, n=6 Coefficients SE P
Intercept 3.711 0.157 ≤0.000
PTT −0.009 0.005 0.168
Table 6C
P/F ratio day 8 r Adjusted r2 p-ANOVA
vs placebo day 0 0.097 0.935 0.002
vs GC day 0 0.833 0.694 0.016
vs placebo day 7 0.978 0.932 0.002
vs GC day 7 0.978 0.932 0.002
PP day 2
vs placebo day 0 none - -
vs GC day 0 none - -
vs placebo day 7 1 1 ≤0.000
vs GC day 7 none - -
PaCO2 day 2
vs placebo day 0 none - -
vs GC day 0 none - -
vs placebo day 7 none - -
vs GC day 7 none - -
Racemic epinephrine
vs placebo day 0 0.809 0.604 0.001
vs GC day 0 none - -
vs placebo day 7 0.978 0.936 0.002
vs GC day 7 none - -
O2 at transfer
vs placebo day 0 1 1 ≤0.000
vs GC day 0 none - -
vs placebo day 7 1 1 ≤0.000
vs GC day 7 0.991 0.970 0.002
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